Hyperpigmentation as a rare side effect of adalimumab

Affiliations

¹ Dermatology Department, Hospital de Santarém EPE, Santarém, Portugal.
² Pathological Anatomy Department, Hospital de Santarém EPE, Santarém, Portugal.

Francisco Gil et al. Int J Dermatol. 2021 Mar.

. 2021 Mar;60(3):e105-e106.

doi: 10.1111/ijd.15268. Epub 2020 Oct 27.

¹ Dermatology Department, Hospital de Santarém EPE, Santarém, Portugal.
² Pathological Anatomy Department, Hospital de Santarém EPE, Santarém, Portugal.

No abstract available

References

1. Blomberg M, Zachariae CO, Grønhøj F. Hyperpigmentation of the face following adalimumab treatment. Acta Derm Venereol 2009; 89: 546-547.
1. Bertrand A, Costa K, Dereure O, et al. Une pigmentation atypique et inhabituelle du visage sous adalimumab. Ann Dermatol Venerol 2017; 144: 332-333.
1. Santos-Juanes J, Coto P, Mallo S, et al. Multiple lentigines confined to resolving psoriatic plaques in a patient treated with adalimumab. Dermatology 2008; 216: 279.
1. Gilardi L, Asnal C, Cowan P, et al. Adalimumab-linked reversible lentiginosis. Glob Dermatol 2018; 4: 1-2.
1. Muller G, Milman L, Boff A, et al. Acanthosis nigricans in areas of resolving psoriatic plaques after adalimumab therapy. J Clin Exp Dermatol Res 2016; 7: 1-2.